skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Conatumumab (Code C71015)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Conatumumab

Definition: A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.

Display Name: Conatumumab

Label: Conatumumab

NCI Thesaurus Code: C71015 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2346822  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
AMG 655
Anti-TRAIL Receptor 2 Monoclonal Antibody AMG 655
Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Receptor Superfamily Member 10b (Death Receptor 5, Trail-R2, CD262 Antigen))
Monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))Gamma-1 Heavy Chain (225-215')-Disulphide With Kappa Light Chain (231-231'':234-234'')-Bisdisulphide Dimer

External Source Codes: 
CAS Registry Number 896731-82-1 (see NLM ChemIDplus info)
FDA UNII Code 1P48L61KM0
PDQ Closed Trial Search ID 573083
PDQ Open Trial Search ID 573083 (check for NCI PDQ open clinical trial info)
UMLS CUI C2346822

Other Properties:
     Name Value (qualifiers indented underneath)
code C71015
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-TRAIL_Receptor_2_Monoclonal_Antibody_AMG_655
Semantic_Type Amino Acid, Peptide, or Protein

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom